BIO-key International (BKYI) AI Stock Analysis

• Market Cap: $5.35M
• Dividend Yield: N/A
• Average Volume (3M): 120.72K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.35
• Revenue Growth: 13.96%
• EPS Growth: 85.22%
• Country: US
• Employees: 41
• Sector: Industrials
• Sector Strength: 72
• Industry: Security & Protection Services
• EPS (TTM): -0.20
• Shares Outstanding: 6,863,776
• 10 Day Avg. Volume: 155,980
• 30 Day Avg. Volume: 120,715
• PEG Ratio: 0.02
• Price to Book (P/B): 1.75
• Price to Sales (P/S): 0.95
• P/FCF Ratio: -2.26
• Enterprise Value/Market Cap: 0.58
• Enterprise Value/Revenue: 0.45
• Enterprise Value/Gross Profit: 0.57
• Enterprise Value/Ebitda: -0.93
• 1Y Price Target: $1.50
• Price Target Upside: 97.37% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 48 Neutral
• Price Target: $1.00 ▲(31.58% Upside)

BIO-key International's overall stock score is primarily influenced by its challenging financial performance and valuation concerns. Despite positive developments in revenue growth and strategic expansions highlighted in the earnings call, the company's ongoing profitability issues and negative cash flow metrics weigh heavily on the score.

Positive Factors

Revenue Growth

The significant revenue growth indicates a strong demand for BIO-key's products, suggesting the company is successfully expanding its market presence and product adoption, which is crucial for long-term sustainability.

Strategic Expansions

Securing international defense contracts enhances BIO-key's market position and diversifies its revenue streams, providing a foundation for sustained growth and competitive advantage.

Expense Management

Effective expense management through reduced SG&A costs improves operational efficiency, which can lead to better profitability and financial health over the long term.

Negative Factors

Negative Cash Flow

Persistent negative cash flow indicates challenges in generating sufficient cash from operations, which can limit the company's ability to invest in growth and manage financial obligations.

Profitability Issues

Ongoing losses highlight operational inefficiencies and the need for continued revenue growth to achieve profitability, posing a risk to long-term financial stability.

Decline in Gross Margin

A declining gross margin, despite revenue growth, suggests pressure on profitability due to lower-margin product sales, which could impact future earnings potential.

BIO-key International Business Overview & Revenue Model

Company Description

BIO-key International, Inc. develops and markets fingerprint identification biometric technology and software solutions, and enterprise-ready identity access management solutions for commercial, government, and education customers in the United States and internationally. The company offers BIO-key PortalGuard and PortalGuard IDaaS solutions, a customer-controlled and neutral-by-design cloud-based identity platform that allows customers to integrate with any cloud or on-premises SaaS application, as well as windows device authentication through IAM platform. Its solutions enable its customers to secure their workforces and student populations; and make their partner networks more collaborative. In addition, it provides BIO-key VST and WEB-key products; and Civil and Large-Scale ID Infrastructure solutions that develops finger-based biometric technology. Further, it offers finger scanners for enterprise and consumer markets under SideSwipe, EcoID, and SidePass brand names. The company was formerly known as SAC Technologies and changed its name to BIO-key International, Inc. in 2002. BIO-key International, Inc. was founded in 1993 and is headquartered in Wall, New Jersey.

How the Company Makes Money

BIO-key generates revenue through multiple streams, primarily by selling biometric hardware and software solutions to businesses and government entities. Their revenue model includes direct product sales, software licensing fees, and subscription services for their identity management platforms. Additionally, the company may enter into strategic partnerships that enhance its product offerings or expand its market reach, contributing to revenue growth. Ongoing maintenance and support services for their installed systems also provide a recurring revenue stream, while consulting services related to biometric implementations further bolster their earnings.

BIO-key International Financial Statement Overview

Summary

BIO-key International faces significant financial challenges, with negative profitability and cash flow metrics. Despite improvements in gross profit margin and managed debt levels, the company struggles with consistent revenue growth and cash generation, indicating potential risks.

Income Statement

The company's income statement reveals a challenging financial position with persistent negative net income and EBIT. The gross profit margin has improved significantly from earlier years, indicating better cost control, yet the negative EBIT and net profit margins suggest ongoing operational inefficiencies. Revenue growth has been erratic, with notable increases in some years but an overall lack of consistent upward trajectory.

Balance Sheet

The balance sheet reflects a mixed situation. The debt-to-equity ratio is relatively low, suggesting manageable debt levels compared to equity. However, the equity ratio shows a moderate reliance on liabilities to finance assets. Return on equity remains negative due to continuous losses, highlighting profitability issues. Overall, the balance sheet shows some stability but is weakened by ongoing profitability concerns.

Cash Flow

The cash flow statement shows significant negative operating cash flow, which overshadows the company's financial flexibility. Free cash flow has consistently been negative, indicating challenges in generating sufficient cash from operations. The high operating cash flow to net income ratio suggests potential cash flow generation issues. Despite some positive financing cash flow, the cash flow position remains concerning.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.91M	6.93M	7.75M	7.02M	5.11M	2.84M
Gross Profit	5.44M	5.64M	1.43M	4.58M	3.44M	2.04M
EBITDA	-3.37M	-3.55M	-7.85M	-11.37M	-4.53M	-4.90M
Net Income	-4.21M	-4.30M	-8.52M	-11.91M	-5.07M	-9.67M
Balance Sheet
Total Assets	10.52M	8.62M	4.52M	11.91M	17.77M	22.52M
Cash, Cash Equivalents and Short-Term Investments	2.28M	437.60K	511.40K	2.64M	7.75M	17.51M
Total Debt	61.62K	1.78M	365.35K	3.24M	264.16K	730.47K
Total Liabilities	3.66M	4.84M	3.45M	4.85M	2.19M	2.19M
Stockholders Equity	6.85M	3.77M	1.06M	5.30M	15.58M	20.34M
Cash Flow
Free Cash Flow	-3.52M	-2.93M	-3.79M	-6.31M	-9.02M	-4.99M
Operating Cash Flow	-3.51M	-2.91M	-3.79M	-6.23M	-8.98M	-4.95M
Investing Cash Flow	-17.23K	-13.05K	-1.00K	-696.62K	-42.02K	-2.23M
Financing Cash Flow	4.41M	2.83M	1.43M	1.90M	-218.60K	24.09M

BIO-key International Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.76
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BKYI, the sentiment is Negative. The current price of 0.76 is below the 20-day moving average (MA) of 0.77, below the 50-day MA of 0.78, and below the 200-day MA of 0.96, indicating a bearish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 47.58 is Neutral, neither overbought nor oversold. The STOCH value of 20.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BKYI.

BIO-key International Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SPCB	59 Neutral	57.36M	36.86	5.65%	―	―	―
VRME	50 Neutral	11.28M	-2.65	-26.23%	―	-13.20%	-89.43%
BKYI	48 Neutral	$5.35M	―	-145.28%	―	13.96%	85.22%
DGLY	46 Neutral	3.52M	―	-119.56%	―	-20.52%	83.27%
KSCP	44 Neutral	55.60M	-0.58	-205.74%	―	-6.61%	―
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%

BIO-key International Corporate Events

BIO-key International Approves Stock Plan Amendments

On August 8, 2025, BIO-key International, Inc. held its Annual Meeting of Stockholders, where amendments to two stock plans were approved. The amendments increased the number of shares available for issuance under both the 2023 Stock Incentive Plan and the 2021 Employee Stock Purchase Plan by 700,000 shares each, potentially enhancing employee engagement and investment opportunities.

The most recent analyst rating on (BKYI) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on BIO-key International stock, see the BKYI Stock Forecast page.

BIO-key International Approves Key Proposals at Annual Meeting

On August 8, 2025, BIO-key International, Inc. held its Annual Meeting of Stockholders, where several key proposals were approved. These included the election of board members, ratification of the company’s accounting firm, approval of executive compensation, and amendments to stock incentive and employee stock purchase plans. These decisions are expected to impact the company’s governance and operational strategies positively.

The most recent analyst rating on (BKYI) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on BIO-key International stock, see the BKYI Stock Forecast page.